Access and quality of biomarker testing for precision oncology in Europe.
Normanno N. et al.
Eur J Cancer 2022;:70-77

Lessons Learned, Challenges Taken, and Actions Made for "Precision" Immunohistochemistry. Analysis and Perspectives From the NordiQC Proficiency Testing Program.
Nielsen S. et al.
Appl Immunohistochem Mol Morphol 2023;7:452-458

A Consortium for Analytic Standardization in Immunohistochemistry.
Bogen SA. et al.
Arch Pathol Lab Med 2022;5:584-590

Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT).
Hurwitz JT. et al.
Oncol Ther 2022;2:391-409

Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.
Kristoffersen HL. et al.
Appl Immunohistochem Mol Morphol ;5:326-332

NordiQC Assessments of Synaptophysin Immunoassays.
Vyberg M. et al.
Appl Immunohistochem Mol Morphol 2021;9:643-647

NordiQC Assessments of Keratin 5 Immunoassays.
Thomsen C. et al.
Appl Immunohistochem Mol Morphol 2020;7:566-570

Ki-67 Proliferation Index in Breast Cancer as a Function of Assessment Method: A NordiQC Experience.
Røge R. et al.
Appl Immunohistochem Mol Morphol 2021;2:99-104

Image Analyses Assessed Cell Lines as Potential Performance Controls of Ki-67 Immunostained Slides.
Røge R. et al.
Appl Immunohistochem Mol Morphol 2021;2:95-98

Impact of Primary Antibody Clone, Format, and Stainer Platform on Ki67 Proliferation Indices in Breast Carcinomas.
Røge R. et al.
Appl Immunohistochem Mol Morphol 2019;10:732-739

"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.
Torlakovic E. et al.
Mod Pathol 2020;1:4-17

NordiQC Assessments of CD117 Immunoassays.
Røge R. et al.
Appl Immunohistochem Mol Morphol 2019;2:87-91

NordiQC Assessments of MSH6 Immunoassays.
Vyberg M. et al.
Appl Immunohistochem Mol Morphol 2018;7:431-434

Uneven Staining in Automated Immunohistochemistry: Cold and Hot Zones and Implications for Immunohistochemical Analysis of Biopsy Specimens.
Cheung CC. et al.
Appl Immunohistochem Mol Morphol 2018;5:299-304

NordiQC Assessments of PAX8 Immunoassays.
Røge R. et al.
Appl Immunohistochem Mol Morphol 2018;4:221-224

NordiQC Assessments of Low Molecular Weight Keratin 8/18 Immunoassays.
Vyberg M. et al.
Appl Immunohistochem Mol Morphol 2017;10:673-678

Accurate PD-L1 Protocols for Non-Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3.
Røge R. et al.
Appl Immunohistochem Mol Morphol 2017;6:381-385

Virtual Double Staining: A Digital Approach to Immunohistochemical Quantification of Estrogen Receptor Protein in Breast Carcinoma Specimens.
Lykkegaard Andersen N. et al.
Appl Immunohistochem Mol Morphol 2018;9:620-626

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories.
Torlakovic EE. et al.
Appl Immunohistochem Mol Morphol 2017;3:151-159

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.
Torlakovic EE. et al.
Appl Immunohistochem Mol Morphol 2017;2:79-85

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry.
Cheung CC. et al.
Appl Immunohistochem Mol Morphol 2017;4:227-230

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers.
Cheung CC. et al.
Appl Immunohistochem Mol Morphol 2017;1:4-11

Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas.
Nielsen SL. et al.
Appl Immunohistochem Mol Morphol 2017;5:320-328

Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining.
Røge R. et al.
Breast Cancer Res Treat 2016;1:11-19

Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests.
Vyberg M. et al.
BMC Health Serv Res 2015:352

Proficiency testing in immunohistochemistry--experiences from Nordic Immunohistochemical Quality Control (NordiQC).
Vyberg M. et al.
Virchows Arch 2016;1:19-29

Getting controls under control: the time is now for immunohistochemistry.
Torlakovic EE. et al.
J Clin Pathol 2015;11:879-82

External quality assessment for immunohistochemistry: experiences from NordiQC.
Nielsen S. et al.
Biotech Histochem 2015;5:331-40

Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee.
Torlakovic EE. et al.
Appl Immunohistochem Mol Morphol 2015;1:1-18

Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel.
Torlakovic EE. et al.
Appl Immunohistochem Mol Morphol 2014;4:241-52

Carb-3 is the superior anti-CD15 monoclonal antibody for immunohistochemistry.
Røge R. et al.
Appl Immunohistochem Mol Morphol 2014;6:449-58

Demonstration of CDX2 is highly antibody dependant.
Borrisholt M. et al.
Appl Immunohistochem Mol Morphol 2013;1:64-72

Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.
Torlakovic EE. et al.
Am J Clin Pathol 2010;3:354-65

Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry.
Yaziji H. et al.
Appl Immunohistochem Mol Morphol 2008;6:513-20

2023 USCAP: Evolution in the Use of On-Slide Controls for Diagnostic Immunohistochemistry in the Era of Precision Testing. Abstract: mar. 2023, I: Laboratory Investigation. 103, Suppl. 3

2023 USCAP: Digital Image Analysis-Aided Assessment of HER2 Immunohistochemistry for External Proficiency Testing. Abstract: mar. 2023, I: Laboratory Investigation. 103, Suppl. 3

2023 ECP: Evaluation of Tonsil as Tissue Control for Immunohistochemical Demonstration of Estrogen Receptor. Abstract: sep. 2023, I: Virchows Archiv. 483, Suppl. 1

2022 USCAP: Results of PD-L1 ”Fit-For-Purpose” Proficiency Testing in NordiQC. Abstract: mar. 2022, I: Modern Pathology. 35, Suppl. 2

2020 ECP: PD-L1 assays and their performance in NordiQC. Abstract: 2020, I: Virchows Archiv. 477, Suppl.

2024 USCAP: Dual Contribution of Quantitative Image Analysis for the Evaluation of HER2 IHC Staining Quality, and Interpretation of HER2 Overexpression and HER2-Low Status in Breast Carcinoma. Abstract: 2024, I: Laboratory Investigation. 104, Issue 3, Suppl

2024 USCAP: Improving the Quality of IHC: Impact of Tailored Advice and Reassessment After a Failed External Quality Assessment Result. Abstract: 2024, I: Laboratory Investigation. 104, Issue 3, Suppl

2024 USCAP: Evaluation of Cell Lines in Combination with Artificial Intelligence as Quality Tools to Monitor HER2 IHC Test Reproducibility. Abstract: 2024, I: Laboratory Investigation. 104, Issue 3, Suppl

2024 ECP: Inter-assay comparison of two PD-L1 IHC 22C3 pharmDx assays for Dako Autostainer Link 48 (SK006) and Dako Omnis (GE006) in different cancer types. Abstract: 36th European Congress of Pathology – Abstracts. Virchows Arch 485 (Suppl 1), 1–546 (2024).

2024 ECP: TRPS1 in Breast Cancer: A comparative study of five different IHC assays. Abstract: 36th European Congress of Pathology – Abstracts. Virchows Arch 485 (Suppl 1), 1–546 (2024).

2024 ECP: Comparative Analysis of Six Different IHC Assays for Epithelial Cell Adhesion Molecule (EpCAM) in Carcinomas. Abstract: 36th European Congress of Pathology – Abstracts. Virchows Arch 485 (Suppl 1), 1–546 (2024).

Proforma invoice for returning slides